*3.1.1.2.1 Case study1: synthesis of Pazopanib hydrochloride [Votrient®, GW786034, 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2 methylbenzenesulfonamide. HCl, (21)]*

Pazopanib [Votrient®, GW786034, 5-[[4-[(2,3-dimethylindazol-6-yl) methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide (21)] is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/b, and c-kit. The drug blocks tumor growth and inhibits angiogenesis. It was approved for renal cell carcinoma by the U.S. Food in 2009 and advanced soft tissue sarcoma [59]. The drug is marketed under the trade name Votrient by the drug's manufacturer, GlaxoSmithKline [59].
